Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a gadolinium-based contrast agent presented as a solution for injection for intravenous use. It enhances magnetic resonance imaging (MRI) contrast in patients undergoing diagnostic imaging procedures. GNH USA supplies Omniscan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Omniscan (gadodiamide) is used as a gadolinium‑based contrast agent for magnetic resonance imaging procedures.

- Magnetic resonance imaging (MRI): Provides enhanced visualization of anatomical structures and pathology. - Magnetic resonance angiography (MRA): Improves delineation of vascular anatomy and blood flow. - Contrast‑enhanced central nervous system studies: Facilitates detection of lesions, tumors, and vascular abnormalities.

Adverse reactions may occur following administration of gadodiamide.

Common Side Effects: - Nausea: mild to moderate discomfort after injection. - Headache: transient headache reported by some patients. - Injection site pain: brief discomfort at the site of intravenous administration. - Warmth sensation: feeling of warmth or flushing during injection. - Metallic taste: temporary metallic sensation in the mouth. - Dizziness: occasional light‑headedness post‑dose.

Serious or Rare Side Effects: - Allergic reactions: including anaphylaxis, rash, or bronchospasm. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure requiring medical attention. - Seizures: infrequent neurologic events. - Cardiac arrest: extremely rare but life‑threatening event.

Use of gadodiamide requires careful assessment of patient risk factors.

- Renal function assessment: evaluate kidney function before administration, especially in patients with impaired renal function. - Pregnancy: use only if clearly needed; category C indicates potential risk. - Breastfeeding: consider potential exposure and discuss with a healthcare professional. - History of allergic reactions: assess prior contrast media reactions before use. - Concurrent nephrotoxic drugs: monitor renal status closely when combined with other nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gadodiamide may interact with other agents that affect renal function or contrast safety.

Major Interactions (Avoid): - Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid or select alternative contrast. - High‑dose iodinated contrast agents: combined use may heighten nephrotoxicity. - Concurrent gadolinium‑based agents: avoid simultaneous administration of multiple gadolinium products.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance, requiring monitoring of kidney function. - ACE inhibitors or ARBs: can affect renal perfusion; observe renal parameters during co‑administration.